MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
0.8467
+0.0559
+7.07%
Opening 12:05 12/04 EST
OPEN
0.7900
PREV CLOSE
0.7908
HIGH
0.8741
LOW
0.7900
VOLUME
440.57K
TURNOVER
0
52 WEEK HIGH
5.42
52 WEEK LOW
0.6700
MARKET CAP
96.98M
P/E (TTM)
-0.6435
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at KPTI last week (1127-1201)?
Weekly Report · 7h ago
Karyopharm Therapeutics; Promising Potential With 3 Ongoing Phase 3 Studies But Risky
Karyopharm therapeutics has three approved drugs but sales have been disappointing. Selinexor is being evaluated in three phase 3 trials in multiple myeloma, endometrial cancer and myelofibrosis. Kpti's lead candidate is selinexor and the drug has been approved for three indications. The company has a high probability of success in the three trials and has a global commercial infrastructure. However, the company faces fierce competition and has disappointing sales due to competition and toxicity.
Seeking Alpha · 4d ago
Weekly Report: what happened at KPTI last week (1120-1124)?
Weekly Report · 11/27 09:06
Weekly Report: what happened at KPTI last week (1113-1117)?
Weekly Report · 11/20 09:06
Weekly Report: what happened at KPTI last week (1106-1110)?
Weekly Report · 11/13 09:06
Karyopharm Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 11/07 22:54
Karyopharm reports encouraging data for endometrial cancer drug candidate
Karyopharm reports encouraging data for endometrial cancer drug candidate. preliminary data from a phase 3 study of its drug selinexor showed signals of improved overall survival in a subset of patients with tp53 wild-type endometrian cancer. selinexor is already approved in the us to treat multiple myeloma.
Seeking Alpha · 11/06 15:12
Karyopharm : Data In Selinexor-Treated Patients With Endometrial Cancer Shows Improvements In PFS
NASDAQ · 11/06 14:50
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It is evaluating eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.